At AstraZeneca, we aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologics medicines along with scientific research targeting disease modification and early intervention. We are excited to join clinicians, researchers and scientists at the 2017 American Thoracic Society (ATS) Annual Meeting to discuss the latest advancements in respiratory science.
Follow us on Twitter for the latest updates from AstraZeneca at #ATS2017.
Respiratory at AstraZeneca and MedImmune
Since asthma is a complex disease, the same approach cannot be used to treat all patients. Roland Kolbeck, VP, R&D explains how early science comes into AstraZeneca’s approach to the development of respiratory biologics.
What we're working on
We are innovating to target specific biologic treatments to patient types, so that we might optimise individual responses to treatment.
Veeva ID: Z4-4722
Date of next review: May 2018